Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...

Oral Hypoglycemic Agents: Glinides

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...

GPCRs Regulate Adenylyl Cylase Activity

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Functional characterization of Griscelli syndrome type 2 sine albinism in Japanese patients.

Journal of human immunity·2026

Same author

Risk factors for barrett's esophagus identified in a large-scale Japanese community cohort study.

Scientific reports·2026

Same author

Consensus on the diagnosis of Cushing's disease: a collaborative statement from the Korean Endocrine Society and Japan Endocrine Society.

Endocrine journal·2026

Same author

Consensus on the Diagnosis of Cushing's Disease: A Collaborative Statement from the Korean Endocrine Society and Japan Endocrine Society.

Endocrinology and metabolism (Seoul, Korea)·2026

Same author

Highlights from the session "BP Management and Variability" at the 2025 Annual Scientific Meeting of the Japanese Society of Hypertension.

Hypertension research : official journal of the Japanese Society of Hypertension·2025

Same author

NRF2 activation by CDDO-Im regulates inflammatory and autophagy pathways in human microglial cells.

Free radical biology & medicine·2025

Search research articles

Related Experiment Video

Updated: Jun 3, 2026

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells

Published on: March 28, 2013

PPARγ agonist beyond glucose lowering effect.

Akira Sugawara¹, Akira Uruno, Masataka Kudo

¹Department of Advanced Biological Sciences for Regeneration, Tohoku University Graduate School of Medicine, Sendai, Japan. akiras2i@med.tohoku.ac.jp

The Korean Journal of Internal Medicine

|March 26, 2011

Summary

This summary is machine-generated.

Peroxisome proliferator-activated receptor gamma (PPARγ) agonists offer significant vascular, renal, and anti-cancer benefits beyond glucose control. These compounds show promise for treating various diseases, including cardiovascular and kidney conditions.

Keywords:

Angiotensin II Endothelium Kidney Thiazolidinediones Thromboxane

Related Experiment Videos

Last Updated: Jun 3, 2026

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells

Published on: March 28, 2013

Area of Science:

Endocrinology
Pharmacology
Cardiovascular Medicine

Background:

Nuclear hormone receptor PPARγ is activated by agonists like thiazolidinediones.
PPARγ agonists exhibit beneficial vascular effects independent of glucose lowering.
These agonists influence the renin-angiotensin-aldosterone system (RAAS).

Purpose of the Study:

To review the pleiotropic effects of PPARγ agonists.
To explore their impact on blood pressure, atherosclerosis, and renal function.
To discuss their potential anti-neoplastic and therapeutic applications.

Main Methods:

Review of existing literature on PPARγ agonists.
Analysis of studies investigating effects on RAAS, endothelial function, and atherosclerosis.
Examination of data on renal protection and anti-cancer properties.

Main Results:

PPARγ agonists lower blood pressure by suppressing RAAS.
They inhibit atherosclerosis progression and protect endothelial function.
Renal protection, including albuminuria reduction, and anti-neoplastic effects are observed.

Conclusions:

PPARγ agonists possess multiple therapeutic actions.
They offer novel treatment strategies for lifestyle-related diseases.
Further research into their pleiotropic effects is warranted.